<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOMOTIL - diphenoxylate hydrochloride and atropine sulfate tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each Lomotil tablet and each 5 ml of Lomotil liquid for oral use 
contains: </p>
<p>diphenoxylate hydrochloride   2.5 mg</p>
<p>atropine sulfate ................. 0.025 mg</p>
<p>Diphenoxylate hydrochloride, an antidiarrheal, is ethyl 
1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride and has 
the following structural formula:</p>
<div class="Figure"><img alt="image of chemical structure for diphenoxylate hcl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2b171be-ac59-48ec-84da-03d3f2d34ca6&amp;name=chemical_structure%20of%20diphenoxylate%20hcl.jpg"></div>
<br><br>Atropine sulfate, an anticholinergic, is endo-(±)-α-(hydroxymethyl) 
benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1] oct-3-yl ester sulfate (2:1) 
(salt) monohydrate and has the following structural formula:<div class="Figure"><img alt="image of chemical structure for atropine sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2b171be-ac59-48ec-84da-03d3f2d34ca6&amp;name=chemical_structure%20of%20atropine%20sulfate.jpg"></div>A subtherapeutic amount of atropine sulfate is present to discourage 
deliberate overdosage.
<p>Inactive ingredients of Lomotil tablets include acacia, corn starch, 
magnesium stearate, sorbitol, sucrose, and talc. Inactive ingredients of Lomotil 
liquid include cherry flavor, citric acid, ethyl alcohol 15%, glycerin, sodium phosphate, sorbitol, and water.</p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Diphenoxylate is rapidly and extensively metabolized in man by 
ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active 
and the major metabolite in the blood. After a 5-mg oral dose of carbon-14 
labeled diphenoxylate hydrochloride in ethanolic solution was given to three 
healthy volunteers, an average of 14% of the drug plus its metabolites was 
excreted in the urine and 49% in the feces over a four-day period. Urinary 
excretion of the unmetabolized drug constituted less than 1% of the dose, and 
diphenoxylic acid plus its glucuronide conjugate constituted about 6% of the 
dose. In a 16-subject crossover bioavailability study, a linear relationship in 
the dose range of 2.5 to 10 mg was found between the dose of diphenoxylate 
hydrochloride (given as Lomotil liquid) and the peak plasma concentration, the 
area under the plasma concentration-time curve, and the amount of diphenoxylic 
acid excreted in the urine. In the same study the bioavailability of the tablet 
compared with an equal dose of the liquid was approximately 90%. The average 
peak plasma concentration of diphenoxylic acid following ingestion of four 
2.5-mg tablets was 163 ng/ml at about 2 hours, and the elimination half-life of 
diphenoxylic acid was approximately 12 to 14 hours.</p>
<p>In dogs, diphenoxylate hydrochloride has a direct effect on circular smooth 
muscle of the bowel that conceivably results in segmentation and prolongation of 
gastrointestinal transit time. The clinical antidiarrheal action of 
diphenoxylate hydrochloride may thus be a consequence of enhanced segmentation 
that allows increased contact of the intraluminal contents with the intestinal 
mucosa.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Lomotil is effective as adjunctive therapy in the management of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Lomotil is contraindicated in patients with</p>
<ol>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to diphenoxylate or atropine. 
</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Obstructive jaundice</span>. 
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> associated with <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span> or 
enterotoxin-producing bacteria.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">LOMOTIL IS <span class="Italics">NOT</span> AN INNOCUOUS DRUG AND 
DOSAGE RECOMMENDATIONS SHOULD BE STRICTLY ADHERED TO, ESPECIALLY IN CHILDREN. 
LOMOTIL IS NOT RECOMMENDED FOR CHILDREN UNDER 2 YEARS OF AGE. OVERDOSAGE MAY 
RESULT IN SEVERE <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span>, POSSIBLY LEADING TO PERMANENT 
<span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">BRAIN DAMAGE</span> OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> (SEE <span class="Italics"><a href="#section-10">OVERDOSAGE</a></span>). THEREFORE, KEEP THIS MEDICATION OUT 
OF THE REACH OF CHILDREN.</p>
<p>THE USE OF LOMOTIL SHOULD BE ACCOMPANIED BY APPROPRIATE FLUID AND ELECTROLYTE 
THERAPY, WHEN INDICATED. IF SEVERE <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">DEHYDRATION</span> OR <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">ELECTROLYTE IMBALANCE</span> IS 
PRESENT, LOMOTIL SHOULD BE WITHHELD UNTIL APPROPRIATE CORRECTIVE THERAPY HAS 
BEEN INITIATED. DRUG-INDUCED INHIBITION OF PERISTALSIS MAY RESULT IN FLUID 
RETENTION IN THE INTESTINE, WHICH MAY FURTHER AGGRAVATE <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">DEHYDRATION</span> AND 
<span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">ELECTROLYTE IMBALANCE</span>.</p>
<p>LOMOTIL SHOULD BE USED WITH SPECIAL CAUTION IN YOUNG CHILDREN BECAUSE THIS 
AGE GROUP MAY BE PREDISPOSED TO DELAYED DIPHENOXYLATE TOXICITY AND BECAUSE OF 
THE GREATER VARIABILITY OF RESPONSE IN THIS AGE GROUP.</p>
<p>Antiperistaltic agents may prolong and/or worsen <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with 
organisms that penetrate the intestinal mucosa (toxigenic <span class="Italics">E. 
coli, <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>, Shigella</span>), and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span> 
associated with broad-spectrum antibiotics. Antiperistaltic agents should not be 
used in these conditions.</p>
<p>In some patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span>, agents that inhibit 
intestinal motility or prolong intestinal transit time have been reported to 
induce toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>. Consequently, patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span> 
should be carefully observed and Lomotil therapy should be discontinued promptly 
if abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> occurs or if other untoward symptoms develop.</p>
<p>Since the chemical structure of diphenoxylate hydrochloride is similar to 
that of meperidine hydrochloride, the concurrent use of Lomotil with monoamine 
oxidase (MAO) inhibitors may, in theory, precipitate <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>.</p>
<p>Lomotil should be used with extreme caution in patients with advanced 
hepatorenal disease and in all patients with abnormal liver function since 
<span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> may be precipitated.</p>
<p>Diphenoxylate hydrochloride may potentiate the action of barbiturates, 
tranquilizers, and alcohol. Therefore, the patient should be closely observed 
when any of these are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<p class="First">Since a subtherapeutic dose of atropine has been added to the 
diphenoxylate hydrochloride, consideration should be given to the precautions 
relating to the use of atropine. In children, Lomotil should be used with 
caution since signs of atropinism may occur even with recommended doses, 
particularly in patients with Down's syndrome.</p>
<a href="http://"></a><a href="http://"></a>Information For Patients<p>INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE 
RECOMMENDED DOSAGE AND TO KEEP LOMOTIL OUT OF THE REACH OF CHILDREN AND IN A 
CHILD-RESISTANT CONTAINER. INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, 
INCLUDING SEVERE <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span>, POSSIBLY LEADING TO PERMANENT 
<span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">BRAIN DAMAGE</span> OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>. Lomotil may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The patient 
should be cautioned regarding activities requiring mental alertness, such as 
driving or operating dangerous machinery. Potentiation of the action of alcohol, 
barbiturates, and tranquilizers with concomitant use of Lomotil should be 
explained to the patient. The physician should also provide the patient with 
other information in this labeling, as appropriate.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>Known drug interactions include barbiturates, tranquilizers, and 
alcohol. Lomotil may interact with MAO inhibitors (see <span class="Italics"><a href="#section-6">Warnings</a></span>).</p>
<p>In studies with male rats, diphenoxylate hydrochloride was found to inhibit 
the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, 
diphenoxylate has the potential to prolong the biological half-lives of drugs 
for which the rate of elimination is dependent on the microsomal drug 
metabolizing enzyme system.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment Of 
Fertility<p>No long-term study in animals has been performed to evaluate 
carcinogenic potential. Diphenoxylate hydrochloride was administered to male and 
female rats in their diets to provide dose levels of 4 and 20 mg/kg/day 
throughout a three-litter reproduction study. At 50 times the human dose (20 
mg/kg/day), female <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was reduced and there was a marked effect on 
fertility as only 4 of 27 females became pregnant in three test breedings. The 
relevance of this finding to usage of Lomotil in humans is unknown.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy<p>Pregnancy Category C. Diphenoxylate hydrochloride has been shown 
to have an effect on fertility in rats when given in doses 50 times the human 
dose (see above discussion). Other findings in this study include a decrease in 
maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 30% at 20 mg/kg/day and of 10% at 4 mg/kg/day. At 10 
times the human dose (4 mg/kg/day), average litter size was slightly 
reduced.</p>
<p>Teratology studies were conducted in rats, rabbits, and mice with 
diphenoxylate hydrochloride at oral doses of 0.4 to 20 mg/kg/day. Due to 
experimental design and small numbers of litters, embryotoxic, fetotoxic, or 
teratogenic effects cannot be adequately assessed. However, examination of the 
available fetuses did not reveal any indication of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Lomotil 
should be used during pregnancy only if the anticipated benefit justifies the 
potential risk to the fetus.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Caution should be exercised when Lomotil is administered to a 
nursing woman, since the physicochemical characteristics of the major 
metabolite, diphenoxylic acid, are such that it may be excreted in breast milk 
and since it is known that atropine is excreted in breast milk.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>Lomotil may be used as an adjunct to the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> 
but should be accompanied by appropriate fluid and electrolyte therapy, if 
needed. LOMOTIL IS NOT RECOMMENDED FOR CHILDREN UNDER 2 YEARS OF AGE. Lomotil 
should be used with special caution in young children because of the greater 
variability of response in this age group. See<span class="Italics"><a href="#section-6"> Warnings</a></span> and <span class="Italics"><a href="#section-11">Dosage and Administration</a></span>. In case of accidental 
ingestion by children, see <span class="Italics"><a href="#section-10">Overdosage</a></span> for recommended treatment.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">At <span class="Italics">therapeutic</span> doses, the following 
have been reported; they are listed in decreasing order of severity, but not of 
frequency:</p>
<p><span class="Italics">Nervous system:</span> <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness of extremities</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>/<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, 
<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="Italics">Allergic:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the gums, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="Italics">Gastrointestinal system:</span> toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, 
<span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, abdominal 
<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</p>
<p>The following atropine sulfate effects are listed in decreasing order of 
severity, but not of frequency: <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, 
<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, dryness of the skin and mucous membranes. These effects may occur, 
especially in children.</p>
<p>THIS MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE 
REACH OF CHILDREN SINCE AN OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span>, POSSIBLY LEADING TO PERMANENT <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">BRAIN DAMAGE</span> OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<a href="http://"></a>Controlled Substance<p class="First">Lomotil is classified as a Schedule V controlled substance by 
federal regulation. Diphenoxylate hydrochloride is chemically related to the 
narcotic analgesic meperidine.</p>
<a href="http://"></a><a href="http://"></a>Drug abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span><p>In doses used for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, whether acute or 
chronic, diphenoxylate has not produced addiction.</p>
<p>Diphenoxylate hydrochloride is devoid of morphine-like subjective effects at 
therapeutic doses. At high doses it exhibits codeine-like subjective effects. 
The dose which produces antidiarrheal action is widely separated from the dose 
which causes central nervous system effects. The insolubility of diphenoxylate 
hydrochloride in commonly available aqueous media precludes intravenous 
self-administration. A dose of 100 to 300 mg/day, which is equivalent to 40 to 
120 tablets, administered to humans for 40 to 70 days, produced opiate 
withdrawal symptoms. Since addiction to diphenoxylate hydrochloride is possible 
at high doses, the recommended dosage should not be exceeded.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">RECOMMENDED DOSAGE SCHEDULES SHOULD BE STRICTLY FOLLOWED. THIS 
MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE REACH OF 
CHILDREN, SINCE AN OVERDOSAGE MAY RESULT IN SEVERE, EVEN FATAL, RESPIRATORY 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span>.</p>
<p><span class="Italics">Diagnosis:</span> Initial signs of overdosage may include 
dryness of the skin and mucous membranes, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, 
<span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> followed by <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, hypotonic reflexes, 
<span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, pinpoint pupils, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> 
may be evidenced as late as 30 hours after ingestion and may recur despite an 
initial response to narcotic antagonists. TREAT ALL POSSIBLE LOMOTIL OVERDOSAGES 
AS SERIOUS AND MAINTAIN MEDICAL OBSERVATION FOR AT LEAST 48 HOURS, PREFERABLY 
UNDER CONTINUOUS HOSPITAL CARE.</p>
<p><span class="Italics">Treatment:</span> In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, induction of 
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastric lavage, establishment of a patent airway, and possibly 
mechanically assisted respiration are advised. <span class="Italics">In 
vitro</span> and animal studies indicate that activated charcoal may 
significantly decrease the bioavailability of diphenoxylate. In noncomatose 
patients, a slurry of 100 g of activated charcoal can be administered 
immediately after the induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or gastric lavage.</p>
<p>A pure narcotic antagonist (eg, naloxone) should be used in the treatment of 
<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> caused by Lomotil. When a narcotic antagonist is 
administered intravenously, the onset of action is generally apparent within two 
minutes. It may also be administered subcutaneously or intramuscularly, 
providing a slightly less rapid onset of action but a more prolonged effect.</p>
<p>To counteract <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> caused by Lomotil overdosage, the 
following dosage schedule for the narcotic antagonist naloxone hydrochloride 
should be followed:</p>
<p><span class="Italics">Adult dosage:</span> An initial dose of 0.4 mg to 2 mg of 
naloxone hydrochloride may be administered intravenously. If the desired degree 
of counteraction and improvement in respiratory functions is not obtained, it 
may be repeated at 2- to 3-minute intervals. If no response is observed after 10 
mg of naloxone hydrochloride has been administered, the diagnosis of 
narcotic-induced or partial narcotic-induced toxicity should be questioned. 
Intramuscular or subcutaneous administration may be necessary if the intravenous 
route is not available.</p>
<p><span class="Italics">Children: </span>The usual initial dose in children is 
0.01 mg/kg body weight given I.V. If this dose does not result in the desired 
degree of clinical improvement, a subsequent dose of 0.1 mg/kg body weight may 
be administered. If an I.V. route of administration is not available, naloxone 
hydrochloride may be administered I.M. or S.C. in divided doses. If necessary, 
naloxone hydrochloride can be diluted with sterile water for injection.</p>
<p>Following initial improvement of respiratory function, repeated doses of 
naloxone hydrochloride may be required to counteract recurrent respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Supplemental intramuscular doses of naloxone hydrochloride may be 
utilized to produce a longer-lasting effect.</p>
<p>Since the duration of action of diphenoxylate hydrochloride is longer than 
that of naloxone hydrochloride, improvement of respiration following 
administration may be followed by recurrent <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. 
Consequently, continuous observation is necessary until the effect of 
diphenoxylate hydrochloride on respiration has passed. This effect may persist 
for many hours. The period of observation should extend over at least 48 hours, 
preferably under continuous hospital care. Although signs of overdosage and 
<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may not be evident soon after ingestion of diphenoxylate 
hydrochloride, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may occur from 12 to 30 hours later.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DO NOT EXCEED RECOMMENDED DOSAGE.</p>
<p><span class="Italics">Adults:</span> The recommended initial dosage is two 
Lomotil tablets four times daily or 10 ml (two regular teaspoonfuls) of Lomotil 
liquid four times daily (20 mg per day). Most patients will require this dosage 
until initial control has been achieved, after which the dosage may be reduced 
to meet individual requirements. Control may often be maintained with as little 
as 5 mg (two tablets or 10 ml of liquid) daily.</p>
<p>Clinical improvement of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">acute diarrhea</span> is usually observed within 48 hours. 
If clinical improvement of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span> after treatment with a maximum daily 
dose of 20 mg of diphenoxylate hydrochloride is not observed within 10 days, 
symptoms are unlikely to be controlled by further administration.</p>
<p><span class="Italics">Children: Lomotil is not recommended in children under 2 
years of age and should be used with special caution in young children</span> 
(see <span class="Italics"><a href="#section-6">Warnings</a></span> and <span class="Italics"><a href="#section-7">Precautions</a>)</span>. The nutritional 
status and degree of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> must be considered. In children under 13 years 
of age, use Lomotil liquid. Do not use Lomotil tablets for this age group.</p>
<p>Only the plastic dropper should be used when measuring Lomotil liquid for 
administration to children.</p>
<p><span class="Italics">Dosage schedule for children:</span> The recommended 
initial total daily dosage of Lomotil liquid for children is 0.3 to 0.4 mg/kg, 
administered in four divided doses. The following table provides an <span class="Italics">approximate </span>initial daily dosage recommendation for 
children.</p>
<a name="iaada12b1-5bcd-41e4-818e-9735eb47a5ab"></a><table width="50%">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First">
<th align="center">Age<br>(years)</th>
<th align="center" colspan="2">Approximate weight</th>
<th align="center">Dosage in ml<br>(four times daily)</th>
</tr>
<tr class="Last">
<th align="center">(kg)</th>
<th align="center">(lb)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="center">2</td>
<td align="center">11–14</td>
<td align="center">24–31</td>
<td align="center">1.5–3.0</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">12–16</td>
<td align="center">26–35</td>
<td align="center">2.0–3.0</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">14–20</td>
<td align="center">31–44</td>
<td align="center">2.0–4.0</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">16–23</td>
<td align="center">35–51</td>
<td align="center">2.5–4.5</td>
</tr>
<tr>
<td align="center">6–8</td>
<td align="center">17–32</td>
<td align="center">38–71</td>
<td align="center">2.5–5.0</td>
</tr>
<tr class="Last">
<td align="center">9–12</td>
<td align="center">23–55</td>
<td align="center">51–121</td>
<td align="center">3.5–5.0</td>
</tr>
</tbody>
</table>
<p>These pediatric schedules are the best approximation of an average dose 
recommendation which may be adjusted downward according to the overall 
nutritional status and degree of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> encountered in the sick child. 
Reduction of dosage may be made as soon as initial control of symptoms has been 
achieved. Maintenance dosage may be as low as one-fourth of the initial daily 
dosage. If no response occurs within 48 hours, Lomotil is unlikely to be 
effective.</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Italics">Tablets</span>—round, white, with SEARLE 
debossed on one side and 61 on the other side and containing 2.5 mg of 
diphenoxylate hydrochloride and 0.025 mg of atropine sulfate, supplied as:</p>
<p><span>NDC Number</span>        <span>Size</span></p>
<p>54868-0427-5        bottle of 10</p>
<p>54868-0427-4        bottle of 12</p>
<p>54868-0427-3           bottle of 30</p>
<p>54868-0427-0         bottle of 100<br></p>
<br><p><span class="Bold">Rx only</span></p>
<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<p class="First"><span class="Italics">Lomotil Tablets</span></p>
<div class="Figure"><img alt="image of 2 package labels (2_a)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2b171be-ac59-48ec-84da-03d3f2d34ca6&amp;name=2_a%20package%20labels.jpg"></div>
<p><img alt="image of 2 package labels (2_b)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2b171be-ac59-48ec-84da-03d3f2d34ca6&amp;name=2_b%20package%20labels.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOMOTIL 		
					</strong><br><span class="contentTableReg">diphenoxylate hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-0427(NDC:0025-0061)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIPHENOXYLATE HYDROCHLORIDE</strong> (DIPHENOXYLATE) </td>
<td class="formItem">DIPHENOXYLATE HYDROCHLORIDE</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATROPINE SULFATE</strong> (ATROPINE) </td>
<td class="formItem">ATROPINE SULFATE</td>
<td class="formItem">0.025 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SEARLE;61</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-0427-5</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-0427-4</td>
<td class="formItem">12  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-0427-3</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-0427-0</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA012462</td>
<td class="formItem">01/19/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3a69020d-7cb5-4dd9-ba44-6ef8d605cd8c</div>
<div>Set id: d2b171be-ac59-48ec-84da-03d3f2d34ca6</div>
<div>Version: 1</div>
<div>Effective Time: 20090930</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
